CDK6 and glioblastoma: Herein we describe topotecan’s ability to act as a novel inhibitor of global SUMOylation and its putative role as an adjuvant therapy in GBM treatment regimens via the inhibition of CDK6 and HIF-1α which promote changes in both GBM cell cycle progression and cellular metabolism.